Author:
Braun S.,Greiner W.,von der Schulenburg J.-M.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference17 articles.
1. Caro J, Getsios D, Migliaccio-Walle K et al. (2003) Rational choice of cholinesterase inhibitor for the treatment of Alzheimer’s disease in Canada: a comparative economic analysis. BMC Geriatrics (electronic resource) 3: 6
2. Caro JJ, Salas M, Ward A et al. (2002) Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer’s disease in the Netherlands. Dement Geriatr Cogn Disord 14(2): 84–89
3. Caro J, Salas M, Ward A et al. (2004) Garfield F. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer’s disease in the health care systems of different countries. Drugs Aging 21(10): 677–686
4. Elwood W (1998) Forgotten economics implication on Alzheimer disease. Pharmaco Economics 167: 3–4
5. Garfield FB, Getsios D, Caro JJ et al. (2002) Assessment of Health Economics in Alzheimer’s Disease (AHEAD): treatment with galantamine in Sweden. Pharmaco Economics 20(9): 629–637
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献